On October 10, Reshape Lifesciences Received Notice From Nasdaq Indicating That Co Is Not In Compliance With $1.00 Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Reshape Lifesciences has received a notice from Nasdaq indicating that the company is not in compliance with the $1.00 minimum bid price requirement, according to an SEC filing.
October 13, 2023 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Reshape Lifesciences has received a notice from Nasdaq for not meeting the $1.00 minimum bid price requirement. This could potentially lead to delisting if not rectified.
Reshape Lifesciences' failure to meet the minimum bid price requirement could lead to its delisting from Nasdaq. This is a significant negative development for the company and could potentially impact its stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100